Study of Empagliflozin to Reduce Inflammation After Coronary Stenting in Patients with Stable Coronary Artery Disease

What this Trial Is About

Researchers are studying the effects of empagliflozin, a drug commonly used to lower glucose in diabetes treatment, on inflammation in patients with stable coronary artery disease CAD undergoing percutaneous coronary intervention PCI. Although empagliflozin has shown benefits for heart failure patients, the exact reasons are unclear, and this study aims to explore its possible anti-inflammatory effects using PCI as a model of inflammation. Participants will receive either empagliflozin or a placebo tablet once daily for at least three days before their scheduled PCI procedure. The empagliflozin dose is 10 mg per day, administered orally. The study compares inflammation levels after the procedure by measuring C-Reactive Protein CRP and other inflammatory markers before the intervention and 18 to 24 hours afterward, aiming to see if empagliflozin reduces the inflammation response compared to placebo. During the study, patients will have blood samples taken before PCI and about one day later to measure changes in CRP levels and other markers of inflammation. The study uses a randomized, quadruple-masked design to ensure unbiased results. Participants will be monitored for safety and inflammation changes, with the primary outcome focusing on CRP level changes following the PCI procedure. The study runs until September 2027.

Effect of Empagliflozin on Inflammation